Resources
29 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/12/2024
Researchers used data from electronic license renewals in 2021 to examine what factors affect the likelihood of providing medication-assisted treatment (MAT) for opioid use disorder. Physicians and nurse practitioners who were younger, practiced in a public or community health center, and offered a sliding fee scale in their practice had a greater likelihood of providing MAT.
Posted 1/26/2024 (updated 3/28/2024)
Posted 2/21/2023 (updated 3/27/2024)
The report provides key findings from the study assessing substance use and recovery stigma by healthcare workers, compared to non-healthcare workers. The stigma that is perceived by people who use drugs or are in recovery (PWUD/IR) was found to be a structural concern as a large population are opting out of going to the doctor, leaving them open to a variety of untreated illnesses.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).
Posted 3/21/2022 (updated 3/27/2024)
People who inject drugs (PWID) are likely to experience wounds and infection related to their injection drug use. Common wounds and infections experienced by PWID include blood poisoning (septicemia), infection of the heart lining (endocarditis), tetanus, hepatitis, bruising, collapsed veins, abscesses and blood clots. Preventing and caring for wounds in PWID requires special consideration of the conditions surrounding drug use.
Posted 4/26/2021 (updated 4/10/2024)
A Protocol Using Empirically Supported Behavioral Treatments for People with Psychoactive Stimulant Use Disorders
Posted 1/20/2021 (updated 4/4/2024)
People who use drugs (PWUD) in the U.S. experience disproportionate adverse health outcomes and mortality as compared with the population as a whole (Lake & Kennedy, 2016; Reisinger, Pratt, Shoenborn, & Druss, 2017). Similar health outcomes have been reported elsewhere, for example in the UK (Neale, 2004), and across 8 other European countries (Bargagli et al., 2006). In the U.S. health outcomes among PWUD are intensified by the overdose pandemic, epidemic rates of HIV, hepatitis A and C, skin and soft tissue infections (CDC Centers for Disease Control and Prevention, 2020; Hagen, Thiede, & Des Jarlais, 2005; Scholl, Seth, Kariisa, Wilson, & Baldwin, 2019), and by structural barriers thwarting health access and utilization.
Posted 12/23/2020 (updated 4/4/2024)
This article presents an important look into stigma of families impacted by NAS and the ways in which healthcare providers must work to combat stigma’s harmful effects, and explores directions for future research of strategies for reducing stigma amongst this population to improve engagement in healthcare and positive heath-seeking behaviors. The authors reported that mothers of infants with NAS experience intensified stigma surrounding SUDs and the challenge of overcoming exclusion, shame, and judgement of their ability to parent. In examining nurses’ perceptions of perinatal women with SUD, the authors found that many struggled with negative attitudes and prejudices towards mothers of infants with NAS that interfered with their ability to provide nonjudgmental care. The authors urge nurses to implement substantial strategies for addressing stigma through tools such as the ACTS script.
Posted 12/23/2020 (updated 4/4/2024)
This toolkit is designed primarily for substance use and child welfare practitioners, as well as other service providers and health system planners who offer services to, or design services with, pregnant women and new mothers who use substances. Much is changing in the substance use and child welfare fields to bring forth approaches that are culturally safe, trauma informed, harm reduction-oriented and participant-driven. This toolkit highlights these advances and invites people working in both systems to think about how we can continue to improve our work, in partnership with the women who use these services.
Posted 10/23/2020 (updated 4/3/2024)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of BUP-ER 100 mg and 300 mg for the management of moderate-to-severe OUD in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product.